NewsRoom Articles - BioMedWire (BMW)

MondayFeb 09, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment

LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This system provides several advantages over technologies that are currently available for treating tumors with proton therapy The LiGHT system also complements LIXTE’s LB-100, which is the company’s lead clinical candidate that’s designed to help boost the activity of both chemotherapy and immunotherapy LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers. Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship…

FridayFeb 06, 2026 10:00 am

New Photodynamic Therapy Offers Hope Against Brain Cancer

A planned preclinical study testing a light-activated therapy that helps to kill residual brain cancer cells after a patient has undergone surgery to remove a tumor has elicited excitement as it could provide a way forward in eliminating microscopic cancer tissue that surgeons are unable to see while surgically removing a cancerous tumor from the brain. During this therapy, a catheter is inserted into the void left after the visible tumor is surgically removed. This catheter glows once the laser is switched on. The resultant light activates a drug that kills any cancer cells left inside the surrounding brain tissues. The drug is contained inside the…

ThursdayFeb 05, 2026 10:00 am

Novel Yeast Cell Platform Promises to Expedite the Development of Immunotherapies

Researchers have developed a technological platform that leverages yeast cells to test and understand new cancer treatments under development. The use of this platform promises to significantly reduce the costs and time needed in the drug development process. Traditionally, immunotherapy treatments required several months to be tested in the lab. With this new method, the testing period could be collapsed to just a matter of days or a few weeks. The findings of this research appeared in the Nature Communications journal and feature the technology dubbed yeast surface display. The system involves using modified yeast cells to behave and respond in a similar way to the behavior and responses of immune…

ThursdayFeb 05, 2026 9:00 am

The Anti-Dilution Playbook: How Earth Science Tech Inc. (ETST) Rewrote the OTC Capital Structure Narrative

The company has issued zero common shares since October 2023, marking a decisive break from typical OTC dilution patterns. A multi-year share repurchase program has retired more than 20 million shares while authorized shares have been reduced by 60%. Earth Science Tech is funding operations and acquisitions through cash flow while legally restricting its future ability to dilute shareholders. In the microcap market, capital formation is often synonymous with dilution. Companies raise money by issuing new shares, frequently at the expense of long-term shareholders, creating a cycle where growth in operations does not translate into growth in per-share value. Against…

WednesdayFeb 04, 2026 11:15 am

Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective

LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell survival and treatment resistance Clinical programs are designed to enhance existing immunotherapies and chemotherapies rather than replace them Multiple active trials across ovarian clear cell cancer, colon cancer, and soft tissue sarcoma support a platform approach Despite decades of progress in oncology, many cancers remain resistant to treatment, not because therapies are unavailable, but because tumor cells adapt. Immunotherapies and chemotherapies can produce meaningful responses, yet durability and consistency remain challenges, particularly in aggressive or rare cancer subtypes. Increasingly, research is shifting toward approaches that improve how well…

TuesdayFeb 03, 2026 10:00 am

Policy Expert Offers Suggestions for Curbing US Health Care Costs

According to recent data, health expenditures in the U.S. reached $5.3 trillion in 2024. That figure equates to 18% of GDP, and is double what is spent on average in other developed countries. Americans are feeling the pinch, and an estimated 100 million individuals in the country have medical debt. This situation is unsustainable. While there is broad agreement that the health care system is in crisis, there are sharp divides on what solutions need to be implemented to fix the skyrocketing cost of health care in the U.S. Jordan Bruneau, the Great Lakes Policy Institute’s director, offers some recommendations that Americans themselves can implement without waiting for lawmakers and other…

MondayFeb 02, 2026 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer

Although CTCL may progress slowly in its early stages, it remains a chronic and ultimately progressive disease for many patients. Front-line therapies for CTCL remain limited and fragmented. Soligenix is advancing a distinct approach to CTCL treatment through the development of HyBryte(TM), also known as SGX301 or synthetic hypericin. Cutaneous T-cell lymphoma (“CTCL”) remains a cancer with limited treatment options, persistent symptoms and long-term quality-of-life challenges for patients, even decades after its classification as a distinct disease. Despite medical advances in oncology, many people living with CTCL continue to cycle through therapies that offer only partial relief or introduce new…

FridayJan 30, 2026 10:30 am

Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape

The World Health Organization’s recent recognition of rare diseases as a global health priority underscores their collective impact. Soligenix remains focused on delivering meaningful progress in rare disease-based therapeutics and public health. In its Specialized Biotherapeutics segment, Soligenix is advancing candidates designed for orphan diseases and other serious conditions where treatment options are limited. As the global burden of rare diseases continues to rise, there is increasing urgency for innovative therapies that address unmet medical needs. More than 300 million people worldwide live with one or more rare diseases, many of which have limited or no approved treatment options, and…

FridayJan 30, 2026 10:00 am

New Compound Could Become a Transformational Brain Cancer Pill

Researchers at the University of Chicago have identified a compound that has shown efficacy in shrinking tumors in the brains of mice. This has created hope that the compound could, in future, be made into a pill that can treat glioblastoma, one of the deadliest forms of brain cancer. Hui Li, PhD, who led the study team, explains that compound A, as the substance is known, attached to a target on glioblastoma that hadn’t been known to serve as a therapeutic target. The researchers used mouse models in their study and they are now working to develop variants of compound A that are suitable for use in clinical trials. So far, 160 versions of this molecule…

ThursdayJan 29, 2026 10:00 am

Circadian Regulation Could Boost Cancer Immunotherapy, New Study Finds

Scientists have found that keeping circadian rhythms, the variations in body processes during the course of the day, in mind while administering immunotherapy could hold the key to boosting treatment outcomes in patients with cancer. The study, which was conducted by teams based at Zhujiang Hospital, Donghai County People’s Hospital and many other national research centers in China, involved conducting an integrated review of recent scientific studies on how circadian rhythms influence the microenvironment within tumors and in turn play a role in the outcomes of immunotherapy treatments, especially therapies aimed at blocking immune checkpoints. Immunotherapy has transformed cancer care in recent years, but the treatment’s effectiveness varies widely for…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment

New Photodynamic Therapy Offers Hope Against Brain Cancer

Novel Yeast Cell Platform Promises to Expedite the Development of Immunotherapies

The Anti-Dilution Playbook: How Earth Science Tech Inc. (ETST) Rewrote the OTC Capital Structure Narrative

Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective

Policy Expert Offers Suggestions for Curbing US Health Care Costs

Soligenix Inc. (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer

Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape

New Compound Could Become a Transformational Brain Cancer Pill

Circadian Regulation Could Boost Cancer Immunotherapy, New Study Finds

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search